Top biopharmaceutical Covid-19 vaccine companies boosted with over 80% revenue growth
Pharmaceutical Technology
SEPTEMBER 15, 2022
Upcoming biosimilar competition for Humira means AbbVie’s focus may turn to Rinvoq, approved in the US for atopic dermatitis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis, and Skyrizi, approved in the US for psoriatic arthritis and plaque psoriasis. AbbVie reported a 22.7% Bristol Myers Squibb (BMS) documented a 9.1%
Let's personalize your content